Lisa LaVange is director of the Office of Biostatistics in the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA). As director, she oversees approximately 215 statistical reviewers and staff members involved in the development and application of statistical methodology for drug regulation.
Prior to joining the FDA, LaVange was professor and director of the Collaborative Studies Coordinating Center in the department of biostatistics in the Gillings School of Global Public Health at The University of North Carolina at Chapel Hill (UNC), where she served as principal investigator for several large-scale multi-center clinical trials, epidemiology studies, and patient registries.
Before joining academia, LaVange spent 10 years in the pharmaceutical industry and 16 years in nonprofit research. Her research interests include the design and analysis of clinical trials and complex sample surveys, and her fields of application include medical research and drug development, with a focus on rare disease and health disparities.
US Food and Drug Administration
LaVange earned her BA in mathematics at UNC, her MA in mathematics at the University of Massachusetts – Amherst, and her PhD in biostatistics at UNC. She served as president of the Eastern North American Region of the International Biometric Society and on the IBS Executive Board. She was formerly co-editor of the Journal of Pharmaceutical Statistics and editor-in-chief of the ASA-SIAM book series. She is a Fellow and the 2018 president of the American Statistical Association.
For information about this talk, please visit the online program.